Skip to content
Open access

Immunogenicity up to age 5 years following a single-dose or two-dose infant primary series of 10-valent or 13-valent pneumococcal conjugate vaccine each followed by a booster dose in South Africa: extended follow-up of a single-centre, open-label, non-inferiority, randomised controlled trial.

Sep 2026 · The Lancet Child & Adolescent Health · Vol 10, pp. 797-806 · 0 citations · 30 references
Medicine

TL;DR

A reduced PCV13 1+1 schedule, primed at either 6 weeks or 14 weeks, maintained non-inferior serotype-specific GMCs relative to the PCV13 2+1 schedule up until age 5 years, supporting schedule transition in countries with well established PCV programmes.

Abstract

Background

Reduced-dosing pneumococcal conjugate vaccine (PCV) schedules (single primary dose plus booster [1+1]) are being considered and have been deployed in the UK. We aimed to evaluate the persistence of serotype-specific immunity until age 5 years in infants randomly assigned to 1+1 or two primary doses plus booster (2+1) schedules of 10-valent (PCV10) or 13-valent (PCV13) vaccine.

Methods

In the original, single-centre, open-label, non-inferiority, randomised controlled trial, infants not exposed to HIV were randomly assigned (1:1:1:1:1:1) using block randomisation into the six following groups: single-dose PCV10 or PCV13 at 6 weeks (6w+1) or 14 weeks (14w+1), or two doses of PCV10 or PCV13 at 6 weeks and 14 weeks (2+1), with all receiving a 9-month booster. In this extended follow-up, serotype-specific serum IgG geometric mean concentrations (GMCs) were measured by in-house Luminex assay at age 3 years, 4 years, and 5 years. Non-inferiority was defined as the lower-bound of the 95% CI of the GMC ratio exceeding 0·5 for at least ten of the PCV13 serotypes and at least eight of the PCV10 serotypes. This follow-up study is registered at ClinicalTrials.gov (NCT04275284).

Findings

In the original trial, of the 1695 who were screened, 600 children were enrolled and randomly assigned to six study groups (100 in each group) from Jan 9 to Sept 20, 2017. Of these, 354 (59%) were included in the follow-up study, including 54 from 6w+1 PCV10, 56 from 14w+1 PCV10, 64 from 2+1 PCV10, 60 from 6w+1 PCV13, 57 from 14w+1 PCV13, and 63 from the 2+1 PCV13 study groups. 986 blood samples were collected across three annual visits (349 at 3 years, 334 at 4 years, and 303 at 5 years) between Feb 18, 2020 and Aug 24, 2022. Both PCV13 1+1 schedules remained non-inferior to the PCV13 2+1 schedule up until age 5 years. Both PCV10 1+1 schedules met non-inferiority at 3 years but did not meet the non-inferiority criteria at 4 years and 5 years. Comparison of the PCV10 2+1 and PCV13 2+1 schedules demonstrated similar IgG GMCs for the ten shared serotypes up until age 5 years, with PCV13 outperforming PCV10 across most serotypes in 1+1 groups.

Interpretation

A reduced PCV13 1+1 schedule, primed at either 6 weeks or 14 weeks, maintained non-inferior serotype-specific GMCs relative to the PCV13 2+1 schedule up until age 5 years, supporting schedule transition in countries with well established PCV programmes. The PCV10 1+1 schedules did not meet non-inferiority criteria compared with the PCV10 2+1 schedule by age 4 years.

Funding

Gates Foundation and South African Medical Research Council.

Read PDF

Similar papers

Clinical trial Open access Oct 2026

Safety and immunogenicity of the 24-valent pneumococcal conjugate vaccine in healthy Chinese adults: two single-center, randomized, double-blind Phase 1 and Phase 2 trials.

BACKGROUND Conventional pneumococcal vaccines cover limited serotypes. This study evaluated the safety and immunogenicity of 24-valent pneumococcal conjugate vaccine (PCV24) in Chinese adults aged ≥18 years. RESEARCH DESIGN AND METHODS Two single-center, randomized, double-blind Phase 1/2 trials were conducted. Two h...

Kang-Ning Wang, Jia-Lei Hu, Hua-Gen Chen et al. · 0 citations
Open access Oct 2026

Phase 2 trial to evaluate the safety and immunogenicity of a 25-valent pneumococcal conjugate vaccine (IVT-PCV25) in infants.

Although the results suggest that IVT-PCV25 has the potential to broaden serotype coverage, there is scope for formulation optimisation by rebalancing serotype-antigen quantities, and IVT-PCV25 had an acceptable safety profile.

L. Bravo, N. Bermal, E. Alberto et al. · 0 citations
Open access Sep 2026

A phase IV parallel-group, open-label, randomized non-inferiority trial evaluating immunogenicity of extended dosing intervals for Euvichol-S oral cholera vaccine in Nairobi, Kenya: study protocol for a randomized non-inferiority trial

Background Global shortages of oral cholera vaccine have led to widespread use of single-dose vaccination. Although this approach increases immediate population coverage, protection may be less durable and effectiveness is lower in young children. Evidence remains limited on whether extending the interval before the se...

E. Osoro, C. Mbae, K. Doyle et al. · 0 citations
Open access Nov 2026

Rationale and design of randomized, double-blind trial evaluating the efficacy of single-dose HPV vaccine efficacy in women aged 18 to 30: The PRISMA trial.

Evidence from the Costa Rica HPV Vaccine Trial suggested that a single dose may provide durable protection in young adult women. Subsequent studies confirmed the non-inferiority of one vs. two doses of the main vaccines among young girls. Vaccination of older cohorts might accelerate cervical cancer elimination, especi...

Byron Romero, Dan-Ping Liu, Rebeca Ocampo et al. · 0 citations
Open access Sep 2026

A randomised, double-blind, placebo-controlled phase I clinical trial to evaluate the safety, tolerability and immunogenicity of three doses of an adjuvanted group B Streptococcus vaccine in older adults aged 55 to 75.

Group B Streptococcus (GBS) disease is an increasing medical burden in adults. The present phase 1 trial evaluated an adjuvanted GBS vaccine (GBS-AlpN) containing N-terminal domains of four alpha-like proteins (AlpNs) (Alp1N, Alp2/3 N, RibN and AlpCN) in 60 healthy adults and 30 with obesity and/or type 2 diabetes (O/D...

Lidia Oostvogels, Azhar Alhatemi, Simon De Gussem et al. · 0 citations
Clinical trial Open access Oct 2026

Evaluating a multi-vaccine respiratory immunization strategy involving SARS-CoV-2, pneumococcal, and influenza vaccines in adults: A randomized, open-label, multicenter, controlled, non-inferiority Phase IV trial in China

ABSTRACT Co-administration of vaccines targeting multiple respiratory pathogens may enhance coverage and streamline adult immunization programs. We conducted a randomized, multicentre, open-label Phase IV trial registered at Chinese Clinical Trial Registry (ChiCTR2100046227) in China to evaluate the immunogenicity and...

Xuan-Wen Shi, Sha-Sha Han, Cong Wu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.